2026年1月15日晚间,成都圣诺生物科技股份有限公司(SH:688117,下称“圣诺生物”)发布2025年度业绩预告。数据显示,公司2025年预计实现归母净利润1.52亿元至1.9亿元,同比增幅区间为204.42%至280.53%;扣非后归母净利润预计为1.49亿元至1.86亿元,同比增幅为226.07%至307.58%。 对于此番业绩增长,圣诺生物明确归因于两大核心因素:一是在建产能的集中...
Source Link2026年1月15日晚间,成都圣诺生物科技股份有限公司(SH:688117,下称“圣诺生物”)发布2025年度业绩预告。数据显示,公司2025年预计实现归母净利润1.52亿元至1.9亿元,同比增幅区间为204.42%至280.53%;扣非后归母净利润预计为1.49亿元至1.86亿元,同比增幅为226.07%至307.58%。 对于此番业绩增长,圣诺生物明确归因于两大核心因素:一是在建产能的集中...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.